My top stock pick for 2019 is a company called Invitae (NYSE: NVTA).
Invitae is one of the leaders in molecular diagnostic testing.
What this means in plain English: through your primary care physician, you can have your entire genome sequenced to determine which diseases you are at high risk of developing.
Invitae is a small company with a market cap of $879 million.
Its mission is to bring comprehensive genetic information into mainstream medicine to improve health care for billions of people.
Invitae wants to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower cost.
Invitae’s growth has been off the charts. In the 3rd quarter of 2018, the company reported an increase in revenue of 106%, driven by 95% increase in volume.
Invitae ended 2018 up 40%, which was great given the carnage the market experienced the last 3 months of the year.
Genomics will play a huge part in in the future of health care. And Invitae will be one of its leaders.
Invitae is not for the faint of heart, because it can be very volatile. However – it is a stock with tremendous growth potential that you should definitely watch.
Disclaimer/Disclosure Statement: Information in this article is not intended to be a recommendation to invest in any stock. Rather, it is presented for readers’ education and consideration when making their own investment decisions. The author is long NVTA.
Click the image of the book at left to be taken to its Amazon page. (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)